Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade

Approval of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab by the FDA in 2004 reflected the success of this vascular targeting strategy in extending survival in patients with advanced cancers. However, consistent with previous reports that experimental tumors can grow or rec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Huang, Jianzhong, Bae, Jae-O, Tsai, Judy P., Kadenhe-Chiweshe, Angela, Papa, Joey, Lee, Alice, Zeng, Shan, Kornfeld, Z. Noah, Ullner, Paivi, Zaghloul, Nibal, Ioffe, Ella, Nandor, Sarah, Burova, Elena, Holash, Jocelyn, Thurston, Gavin, Rudge, John, Yancopoulos, George D., Yamashiro, Darrell J., Kandel, Jessica J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3160826/
https://ncbi.nlm.nih.gov/pubmed/19082480
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados